Navigation Links
Corporate Whistleblower Center Advises Medical Doctors and Pharmaceutical Marketing Reps Who Have Proof of Drug Companies Selling Off-Label Drugs in Any State to Call About Federal Whistleblower Reward Programs
Date:7/15/2014

WASHINGTON, July 15, 2014 /PRNewswire/ -- The Corporate Whistleblower Center is urging a medical doctor, or pharmaceutical company insider to call them at 866-714-6466, if they have well documented proof a drug company is involved in an off labeling scheme that results in Medicare being overbilled, because the rewards for this type of information really can be substantial. http://CorporateWhistleblowerCenter.Com

Photo - http://photos.prnewswire.com/prnh/20140714/126736

Photo - http://photos.prnewswire.com/prnh/20140714/126735

The Corporate Whistleblower Center is urging medical doctors, or drug company marketing representatives to call them at 866-714-6466, if they have well documented proof a drug company is involved in any type of marketing scheme that could end up overbilling Medicare, because the rewards for this type of information can be in the hundreds of thousands, or millions of dollars. http://CorporateWhistleblowerCenter.Com

As an example in April of 2014 the Justice department announced a pharmaceutical company named Astellas Pharma US Inc. will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use. 

The settlement resolves allegations that, between 2005 and 2010, Astellas allegedly marketed and promoted the sale of Mycamine for pediatric use, which was not a medically accepted indication and, therefore, not covered by federal health care programs. During this time period, the FDA approved Mycamine to treat adult patients suffering from serious and invasive infections caused by the fungus Candida, including infections in the esophagus, the blood and the abdomen, and to prevent Candida infections in adults undergoing stem cell transplants. From 2005 through June 2013, however, Mycamine was not approved to treat pediatric patients for any use.   

The Corporate Whistleblower Center says, "We are convinced pharmaceutical companies are currently involved in off labeling marketing schemes that end up costing Medicare millions of dollars each year. We also firmly believe these types off labeling drug schemes are nationwide in every major city like New York, Los Angeles, Boston, Miami, Dallas, Houston, Chicago, Atlanta, Seattle, Detroit, Saint Louis, and in every state.

"If you are a medical doctor, or drug company sales representative in any state, and you have well documented proof of off labeling prescription drugs please call us anytime at 866-714-6466. Unlike any group in the nation we will help you package your information, and then get you to the nation's top whistleblower attorneys, provided there is enough proof to begin the process." http://CorporateWhistleblowerCenter.Com     

The whistleblower in the Astellas settlement will receive $708,852. 

Simple rules for a whistleblower from the Corporate Whistleblower Center:

  • Do not go to the government first, if you are a major whistleblower. The Corporate Whistleblower Center says, "Major whistleblowers frequently go to the federal government thinking they will help. It's a huge mistake. Frequently government officials could care less, or they are incompetent."
  • Do not go to the news media with your whistleblower information. Public revelation of a whistleblower's information could destroy any prospect for a reward.
  • Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, "Fraud is so rampant among federal contractors, that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. We say, come to us first, tell us what type of information you have, and if we think its sufficient, we will help find the right law firms, to assist in advancing your information."

The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas, Massachusetts, Maryland, Virginia, Ohio, Pennsylvania, North Carolina, Georgia, Alabama, Louisiana, Oklahoma, Missouri, Michigan, Indiana, Illinois, Wisconsin, Minnesota, Nebraska, Kansas, Colorado, Utah, New Mexico, Arizona, Nevada, Oregon, Washington, and Alaska.

Any type of insider, or employee, who possesses significant proof of their employer, or a government contractor fleecing the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466, or they can contact the group via their web site at http://CorporateWhistleBlowerCenter.Com.

For attribution purposes please refer to the April 2014 United States Department of Justice press release. http://www.justice.gov/opa/pr/2014/April/14-civ-391.html

The lawsuit is captioned United States ex rel. Smith v. Astellas Pharma, US Inc. et al., No. 10-999 (E.D. Pa.). 

Media Contact:
M. Thomas Martin
866-714-6466


'/>"/>
SOURCE Corporate Whistleblower Center
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Survey Shows eContent Critical to Corporate Strategies
4. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
5. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
6. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
7. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
8. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
9. InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices
10. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
11. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):